Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA tells Genzyme a consent decree to ensure GMP compliance is likely, but firm notes sanctions would be related only to Allston Landing facility.

You may also be interested in...



Facing Manufacturing Woes, Alexion Strengthens Leadership

Martin Mackay, who left AstraZeneca at the end of January after new CEO Pasqual Soriot eliminated his position as head of global R&D, is joining Alexion’s senior management team, even as the highly successful, rare disease-focused biotech seeks to put manufacturing woes behind it.

Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

Belying the adage that no news is good news, embattled Genzyme enjoyed two measures of positive news in the past week. But activist investors continue circling the company, which is not yet out of the deep water

Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

Belying the adage that no news is good news, embattled Genzyme enjoyed two measures of positive news in the past week. But activist investors continue circling the company, which is not yet out of the deep water

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel